30 December 2008
Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma
Andrea Di CataldoABDEF, Daniela DauB, Massimo ConteBDE, Stefano ParodiC, Bruno De BernardiADEFG, Maria GiulianoB, Andrea PessionB, Elisabetta ViscardiF, Roberto LukschD, Aurora CastellanoF, Gregoria BertunaABF, Riccardo HauptCDEMed Sci Monit 2009; 15(1): MT11-18 :: ID: 869520
Abstract
Background
One fourth of infants with disseminated neuroblastoma experience unfavorable outcome. Treatment strategies vary and are based on clinical characteristics at diagnosis which lead to the definition of stage 4 or 4s. To identify the distribution and effect of different prognostic factors, a series of such infants diagnosed in Italy between 1991-1999 was reviewed.
Material and Method
Data were retrospectively retrieved from the Italian Neuroblastoma Registry. One hundred infants, 32 stage 4 and 68 stage 4s, were eligible. Clinical and biological characteristics evaluated at diagnosis for their impact on survival were demographics, primary site, urinary excretion of vanillylmandelic and homovanillic acids, serum neuron specific enolase, LDH, and ferritin together with analysis for MYCN gene, DNA index, and 1p36 chromosome.
Results
Stage 4 prevailed in the second six months of life and stage 4s in the first six months. Events were distributed over two years in stage 4, but occurred very early in stage 4s patients. Survival was respectively 72% and 77.9%. Unfavorable factors were MYCN amplification for both stages, elevated NSE and LDH and normal VMA for stage 4, and di-tetraploid DNA for stage 4s.
Conclusions
The frequency of stage 4s was greater than stage 4. MYCN amplification was the most unfavorable prognostic factor. Survival was similar to previous series, confirming that a part of such infants cannot be cured by current therapies.
Keywords: Prognosis, Vanilmandelic Acid - urine, Survival Rate, Oncogene Proteins - genetics, Phosphopyruvate Hydratase - blood, Nuclear Proteins - genetics, Neuroblastoma - diagnosis, Neoplasm Staging - methods, Neoplasm Metastasis - diagnosis, L-Lactate Dehydrogenase - analysis, Italy, Infant, Newborn, Homovanillic Acid - urine, Genetic Markers - genetics, Ferritins - analysis, Chromosomes, Human, Pair 1 - genetics, Biological Markers - analysis
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
In Press
23 Jun 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical Research
A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...Med Sci Monit In Press; DOI: 10.12659/MSM.937316
21 Jun 2022 : Clinical Research
Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.937016
16 Jun 2022 : Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic EraMed Sci Monit In Press; DOI: 10.12659/MSM.936497
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952